This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Odiparcil

GlaxoSmithKline plc

Drug Names(s): SB-424323

Description: Odiparcil is an orally active glycosaminoglycan enhancer which indirectly enhances thrombin inhibition via heparin cofactor II.

Deal Structure: Odiparcil was originally developed by Solvay.

By October 2006, Solvay had partnered development with GlaxoSmithKline.

In September 2009, Solvay announced that its Board of Directors has decided to sell its pharmaceutical business to Abbott for a total Entreprise Value of about EUR 5.2 billion. This includes a purchase price of EUR 4.5 billion in cash and additional potential payments of up to EUR 300 million if certain milestones are met between 2011 and 2013. The acquisition was completed in February 2010.

Partners: AbbVie Inc.


Odiparcil News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug